Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Revolution Medicines, Inc.
Seagen Inc.
Pfizer
M.D. Anderson Cancer Center
City of Hope Medical Center
Novartis
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AstraZeneca
HUYABIO International, LLC.
HUYABIO International, LLC.
Compugen Ltd
Amal Therapeutics